ALVR - AlloVir, Inc.
AlloVir, Inc.
1100 Winter Street
Waltham, MA 02451
United States
617 433 2605
https://www.allovir.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 111
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. David L. Hallal | Exec. Chairman | 254,38k | N/A | 1966 |
| Dr. Diana M. Brainard M.D. | CEO & Director | 978,99k | N/A | 1971 |
| Mr. Vikas Sinha C.A., CPA, M.B.A. | Pres, CFO & Director | 536,21k | N/A | 1963 |
| Mr. Edward Miller J.D. | Gen. Counsel & Sec. | 618,39k | N/A | 1965 |
| Mr. Brett R. Hagen | Chief Accounting Officer | N/A | N/A | 1973 |
| Mr. Dana M. Alexander | Sr. VP of Technical Operations | N/A | N/A | 1976 |
| Dr. Ann M. Leen Ph.D. | Chief Scientific Officer | N/A | N/A | 1977 |
| Ms. Sonia Choi | Sr. VP of Corp. Affairs & Investor Relations | N/A | N/A | N/A |
| Mr. Agustin Melian M.D. | Advisor | N/A | N/A | 1964 |
| Mr. Ugo Capolino Perlingieri | Head & GM of Europe and Middle East Operations | N/A | N/A | N/A |
Descripción
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
Gobierno corporativo
El ISS Governance QualityScore de AlloVir, Inc., a día 1 de mayo de 2023, es 10. Las puntuaciones base son Auditoría: 7; Tablero: 9; Derechos de los accionistas: 8; Compensación: 10.
